Drug Profile
Azelaprag - Amgen
Alternative Names: AMG-986; BGE-105Latest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; BioAge Labs
- Class Benzene derivatives; Heart failure therapies; Obesity therapies; Pyridines; Pyrimidines; Small molecules; Sulfonamides; Triazoles
- Mechanism of Action Apelin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Muscular atrophy; Obesity
- Discontinued Heart failure
Most Recent Events
- 09 Apr 2024 BioAge Labs and Eli Lily and Company plans a phase II trial in Obesity (Combination therapy, In adults, In the elderly) (PO) in mid of 2024
- 02 Feb 2024 BioAge Labs completes a phase I pharmacokinetic trial in Obseity in New Zealand (PO) (NCT06141889)
- 21 Nov 2023 BioAge plans a Pharmacokinetics phase I trial in Obesity (In volunteers) in New Zealand (PO) in November 2023 (NCT06141889)